The tweet was deleted by the author.
But we saved everything 🙂.
Atossa Therapeutics, Inc. presented its latest developments in breast cancer research at the recent NCCN Annual Conference.
Dr. Sandra Hammer, PhD, delivered a detailed poster presentation covering new scientific advances and ongoing efforts in the field. The event provided an opportunity for Atossa Therapeutics, Inc. to share progress with industry peers and highlight cutting-edge innovation targeting breast cancer. Details shared at the conference are expected to inform further research collaborations and potential clinical applications.
Atossa Therapeutics has recently focused on scaling its precision endocrine therapies in oncology and Duchenne muscular dystrophy. The company has also presented preclinical data on muscle biomarker improvements in dystrophic mice using its (Z)-Endoxifen therapy at the MDA Conference earlier this year. These efforts highlight ongoing research initiatives beyond the current breast cancer developments.